




الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْتِيسْتِي اِسْلَامِي اِنْتَارَا اِنْدُونِيَا

Malaysian Society of
Applied Biology



***In-Vivo* Assessment of *Elettaria cardamomum* Seeds Oil As Potential Antiparasitic Agent Against Haemoflagellate Protozoa, *Trypanosoma evansi* in Mice**



Dr. Mohd Shukri Baba

International Islamic University Malaysia



الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْبَرَسِيَّتِي اِسْتَلَامُ اِنْتَارَا اِيْحْسِيَا مَلْدِيْسِيَا

Malaysian Society of
Applied Biology



INTRODUCTION

Trypanosomiasis




- Vector borne → haemoflagellate & unicellular protozoa
 - *T. b. gambiense* → chronic HAT
 - *T. b. rhodesiense* → acute HAT
 - *T. cruzi* → Chagas disease
- Atypical human trypanosomiasis:
 - *T. vivax* → nagana (cattle & wild)
 - *T. lewisi* → *Rattus* & other rodents
 - *T. congolense* → nagana (camels, dogs, horses, pigs, ruminants)
 - *T. evansi* → surra (mammals)

Atypical Human Trypanosomiasis (aHT) (Philippe et al. 2013)

Patient Number	Location	Trypanosome Species/Sub-species	Date	Parasite Identification Method ^a	Fever	Treatment	Outcome
1	Ghana	<i>T. vivax</i>	1917	Morphology	ND	ND	ND
2	Pasteur Institute	<i>T. b. brucei</i>	1930 ^b	Morphology	ND	ND	ND
3	Congo	<i>T. b. brucei</i>	1947 ^c	Morphology	Present	None	Self-cure
4	Ethiopia	<i>T. b. brucei</i>	1987	Morphology BIIT	ND	ND	Cure
5	Ghana	<i>T. b. brucei</i>	2003	PCR	Present	None	Self-cure
6	Côte d'Ivoire	<i>T. congolense</i>	1998	PCR	Present	Pentamidine	Cure
7	India	<i>T. evansi</i>	1977 ^b	Morphology	Present	Atoxyl	Cure
8	Sri Lanka	<i>T. evansi</i>	1999	Morphology	Present	None	Self-Cure
9	India, Seoni	<i>T. evansi</i>	2004	PCR	Present	Suramin	Cure
10	India, Kolkata	<i>T. evansi</i>	2005	Morphology	Present	None	Death
11	Egypt	<i>T. evansi</i>	2010	Morphology	Present	ND	Cure
12	Malaysia	<i>T. lewisi</i>	1933	Morphology	Present	None	Self-cure
13	India, Parsda	<i>T. lewisi</i>	1974	Morphology	Present	None	Self-cure
14	India, Parsda	<i>T. lewisi</i>	1974	Morphology	Present	None	Self-cure
15	The Gambia	<i>T. lewisi</i> -like	2003	PCR/S	Present	Melarsoprol	Cure
16	Thailand	<i>T. lewisi</i> -like	2003	PCR/S	Present	Antibiotic	Cure
17	India, Mumbai	<i>T. lewisi</i>	2006	Morphology	Present	None	Self-cure
18	India, Pune	<i>T. lewisi</i>	2007	PCR	Present	Suramine	Death
19	India, Bagpat	<i>T. lewisi</i>	2010	PCR/S	Present	Pentamidine	Cure

Trypanosoma evansi

- Animal haemoflagellated protozoa
→ evolutionarily from *T. brucei*
- 1st discovered in 1880 by Sir Griffith Evans in Punjab, India
- Malaysia in 1903 → cow & sheep migration from Thailand
- Atypical human trypanosomiasis (AHT) → 5 human zoonotic cases in India, Egypt and Sri Lanka
- Bad impact & challenges on both human and veterinary medicine



Vectors of Trypanosomiasis

Triatominae bug



Glossinidae fly



Hirudinae / leech



Desmodontinae / vampire bat

Vectors of Atypical Human Trypanosomiasis (aHT)



Argasidae tick / *Ornithodoros*



Horsefly / Tabanidae



Muscidae fly / *Stomoxys*



Horn fly / *Haematobia*

Elettaria cardamomum

- “Queen of Spice” (Ravindran 2010)
- South Asia, SEA, Middle East, Africa and Europe.
- In 100gm → 300kcal, 68g CHO, 15g protein, 28g fibers & no cholesterol
- Vitamin A & C, Na, K, Ca, Fe, Mn, P, Cu, Mg & Zn (Cox et al. 2000)
- Many therapeutic effects & significant biological activities (Gao et al. 2008)



E. cardamomum seeds : Testimonies

- In-vitro inhibits 95% of *Leishmania amazonensis* and *Leishmania braziliensis* promastigotes growth (Denise et al. 2010)
- Inhibits the **synthesis of peptidoglycan** in bilayer lipid structure of organism's plasma membrane (Ogunlana et al. 2013)
- **Anti-colorectal tumour** activity with 68% inhibition rate on human colon adenocarcinoma cells HCA-2 and HCA-7 (Gayathri 2010)
- Curing **asthma** and **bronchitis** symptoms by increasing blood circulation to the lungs (Berhe et al. 2009)
- Oil-based exhibits **anti-gonorrhoea** and **anti-nephritis** property in male rabbit's urethra (Turi et al. 2011)




الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْبَرَسِيَّتِي اِسْتَلَامِيَّةٌ اِنْتَرَا اِيْحْسِيَا مَلَيْسِيَا

Malaysian Society of
Applied Biology




MATERIALS & METHODS

Experimental Items



Work Flow

***T. evansi* stock inoculation**



***T. evansi* i.p. administered (5 × 10³ *T. evansi* / mice)**



0.1 mL 200 µg/kg bw cardamom oil : orally administered



Giemsa blood smear for inhibition rate evaluation



Blood slide for electron microscopic observation



Physical observation of symptoms and mice survival



Blood biochemistry and renal function tests



Vital organ histology for toxicity assessment



Experimental Design

GROUP	REGIME	CODE : DESCRIPTION	DOSAGE
TREATMENT	PREVENTIVE	PRE14 : 14 days pre-infection	0.1 mL 200 µg/kg bw oil (oral)
		PRE7 : 7 days pre-infection	0.1 mL 200 µg/kg bw oil (oral)
		PRE3 : 3 days pre-infection	0.1 mL 200 µg/kg bw oil (oral)
	CONCURRENT	CON : 1 - 2 hours post-infection	0.1 mL 200 µg/kg bw oil (oral)
	CURATIVE	CUR3 : 3 days post-infection	0.1 mL 200 µg/kg bw oil (oral)
		CUR7 : 7 days post-infection	0.1 mL 200 µg/kg bw oil (oral)
CUR14 : 14 days post-infection		0.1 mL 200 µg/kg bw oil (oral)	
CONTROL	POSITIVE	POS : Berenil (Sigma-Aldrich)	0.01 mL 3.5 mg/kg bw (i.p.)
	NEGATIVE	NEG : 0.9 % Normal Saline	0.1 mL 0.9% normal saline (oral)
	LETHAL	LWT : Infection without treatment	5 × 10 ³ <i>T. evansi</i> / mice (i.p.)

- ~ Mice : ICR / ♂ / 6 – 8 weeks old / 25 – 30 g bw / n = 6 per group
- ~ *E. cardamomum* oil & normal saline → daily administered (oral) until the mice die.
- ~ Berenil → administered intraperitoneally (i.p.) as single dose once the parasitemia density = 20 - 30 %.




الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْبَرَسِيَّتِي اِسْتَلَامِيَّةٌ اِنْتَارَا اِيْحْسِيَا مَلِيْسِيَا

Malaysian Society of
Applied Biology




RESULTS & DISCUSSIONS


Parasite Pre-Patent Period



Mice Survival Time





Parasite Growth & Survival in PRE14 Mice : Day 45




Morphological changes of *T. evansi* in PRE14 mice group taken on day 45 as observed under x100 magnification of light microscope (A) and x5000 magnification of SEM (Phillips XL30, UK) (B)

Parasite Growth & Survival in PRE14 Mice : Day 90





Morphological changes of *T. evansi* in PRE14 mice group taken on day 90 as observed under x100 magnification of light microscope (A) and x5000 magnification of SEM (Phillips XL30, UK) (B)

Parasite Growth & Survival in PRE14 Mice : Day 135




Morphological changes of *T. evansi* in PRE14 mice group taken on day 135 as observed under x100 magnification of light microscope (A) and x5000 magnification of SEM (Phillips XL30, UK) (B)

Parasite Growth & Survival in PRE14 Mice : Day 180




Morphological changes of *T. evansi* in PRE14 mice group taken on day 180 as observed under x100 magnification of light microscope (A) and x4000 magnification of SEM (Phillips XL30, UK) (B)

Parasite Growth & Survival in PRE14 Mice : Day 225




Morphological changes of *T. evansi* in PRE14 mice group taken on day 225 as observed under x100 magnification of light microscope (A) and x5200 magnification of SEM (Leo 1450VP, Japan) (B)

Parasite Growth & Survival in PRE14 Mice : Day 275





Morphological changes of *T. evansi* in PRE14 mice group taken on day 275 as observed under x100 magnification of light microscope (A) and x4600 magnification of SEM (Leo 1450VP, Japan) (B)

Parasite Growth & Survival in PRE14 Mice : Day 280 & 281



Reemerged of *T. evansi* which survived in PRE14 mice group on day 280 (A) and day 281 (B) due to the action of 'variable surface glycoprotein (VSA) stochastic genetic modification' as observed under x100 magnification of light microscope.

Parasite Growth & Survival in PRE14 Mice : Day 280 & 281





Reemerged of *T. evansi* which survived in PRE14 mice group on day 280 (A) and day 281 (B) due to the action of 'variable surface glycoprotein (VSA) stochastic genetic modification' as respectively observed under x1600 (A) and x2300 (B) magnification by SEM (Leo 1450VP, Japan).



Parasite Growth & Survival in POS Mice : 1st & 2nd hour





The growth of *T. evansi* in POS mice group taken on 1 hour (left) and 2 hours (right) post-treatment (0.01 mL 3.5 mg/kg bw Berenil) as observed under x100 magnification of light microscope (A1 & B1) and x5000 magnification of SEM electron microscope (Phillips XL30, UK) (A2 & B2)





Parasite Growth & Survival in POS Mice : 3rd & 4th hour





The growth of *T. evansi* in POS mice group taken on 3 hours (left) and 4 hours (right) post-treatment (0.01 mL 3.5 mg/kg bw Berenil) as observed under x100 magnification of light microscope (A1 & B1) and respectively under x3000 (A2) and x2000 (B2) magnification of SEM electron microscope (Phillips XL30, UK)





Parasite Growth & Survival in POS Mice : 5th & 6th hour



The growth of *T. evansi* in POS mice group taken on 5 hours (left) and 6 hours (right) post-treatment (0.01 mL 3.5 mg/kg bw Berenil) as observed under x100 magnification of light microscope (A1 & B1) and x5000 magnification of SEM electron microscope (Phillips XL30, UK) (A2 & B2)



Parasite morphological changes: Cardamom oil vs Berenil



SEM micrograph showed the morphological changes of *T. evansi* in PRE14 mice on 275th day post infection (x5000, Leo 1450VP, Japan), 7 days just before the mice die (A) and in POS mice at 6th hours post infection (x5000, Phillips XL30, UK) (B)

Biochemical Tests For In-Vivo Toxicity Assessment





	TA	TB	TC	TD	CN	CI	NR	Unit
ALT	41.81 ± 2.14	45.20 ± 1.13	67.57 ± 2.91	90.03 ± 2.02	41.03 ± 3.91	44.83 ± 1.11	40 – 93	IU/L
AST	133.13 ± 2.04	125.93 ± 2.12	167.76 ± 2.27	187.01 ± 2.09	111.62 ± 1.19	134.43 ± 4.01	92 – 206	IU/L
ALP	62.76 ± 2.33	59.4 ± 2.97	69.2 ± 2.90	68.03 ± 2.10	61.46 ± 2.46	58.32 ± 2.97	54 – 115	IU/L
STP	6.12 ± 2.32	7.21 ± 3.81	7.93 ± 2.01	8.83 ± 3.90	6.40 ± 1.01	6.80 ± 3.06	5.8 – 9.5	g/dL

- TA : Sub-acute regime – Daily treatment (28 days)
- TB : Sub-acute regime – Daily treatment (28 days) 2 hours post-infection
- TC : Sub-chronic regime – Daily treatment (90 days)
- TD : Sub-chronic regime – Daily treatment (90 days) 2 hours post-infection
- CN : Control regime – Normal mice without infection and treatment
- CI : Control regime – Infected mice on D0
- ALT : Alanine aminotransferase
- AST : Aspartate transaminase
- ALP : Alkaline phosphatase
- STP : Serum total protein




Organ Histology For Toxicity Assessment

RESULTS & DISCUSSION

KIDNEY



LIVER



**Treatment
(Acute)**

**Treatment
(Sub-acute)**

Control



الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْبَرَسِيَّتِي اِسْتَلَامِيَّةٌ اِنْتَارَا اِيْحْسِيَا مَلْدِيْسِيَّتِيَا

Malaysian Society of
Applied Biology



CONCLUSIONS

Hypothesis

- Stochastic genetic modification of VSG is still the best weapon for trypanosome survival (Nok et al. 1996).
- New wave of infection → mice is susceptible to infection (Ogunlana et al. 1944)
- Generally, *E. cardamomum* oil able to prolong the survival rate of the mice although the parasitemia density is quite high
- Significantly, curative regime are less effective than other treatment regimens
- Longer prophylactic duration → longer survival rate of the patient although the parasitemia has reached almost 50%.
- Alteration of dosage, concentration and period of prophylactic treatment → significant antiparasitic activity of cardamom oil.


Suggestions & Future Directions

1. Mechanisms of actions & molecular approaches
2. Extract of *E. cardamomum* daily doable for consumer
3. Play around with different concentration & dosage
4. To deal with stochastic genetic modification of VSG
5. In-vitro screening of *E. cardamomum* oil



الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْبَرَسِيَّتِي اِسْتَلْمَرُ اِنْتَارَا اِيْحْسِيَا مَلْدِيْسِيَا

Malaysian Society of
Applied Biology



REFERENCES

- Philippe, T., Philippe, Bu., Ge´rard, C., Mary, I.G., Jean, J., Prashant, J., Prayag, J., Zhao-Ron, L., Raffaele, M., Etienne, P., Pere, P.S., Marta-Maria, G. T., Louis, T., Philippe V. & Marc, D. 2013. Atypical Human Infections by Animal Trypanosomes. *PLOS Neglected Tropical Disease*. 7(9): e2256
- Ravindran, M.K. 2002. Cardamom: the genus *Elettaria*. New York: *Taylor and Francis*.
- Guidelines. Research Animal Resources, University of Minnesota. Available from: <http://www.ahc.umn.edu/rar/refvalues.html>. Accessed January 8, 2017.
- Gayathri, B., Manjula, N., Vinaykumar, K.S., Lakshmi, B.S. & Balakrishnan, A. 2007. Pure compound from *Boswellia serrata* extract exhibits anti-inflammatory property in human PBMCs and mouse macrophages through inhibition of TNFa, IL-1b, NO and MAP kinases. *Int. Immunopharmacol.* 7, 473-482.
- Cox, S.D., Mann, J.L., Bell, J.E. & Warmington, S.G. 2000. The mode of antimicrobial action of the essential oil of *Melaleuca alternifolia* (tea tree oil). *Journal of Applied Microbiology* 88, 170–175.
- Berhe, N., Wolday, D., Hailu, A., Abraham, Y., Ali, A., Gebre-Michael, T., Desjeux, P., Sonnerborg, A., Akuffo, H. & Britton, S. 1999. HIV viral load and response to leishmanial chemotherapy in coinfecting patients. *AIDS* 13: 1921-192
- Ogunlana, E.O., Hoeglund, S., Onawunmi, G. & Skoeld, O. 1987. Effects of lemongrass oil on the morphological characteristics and peptidoglycan synthesis of *Escherichia coli* cells. *Microbios*, 50, 43–59.
- Zainal-Abidin, B.A.H. 1992. Infections of *Trypanosoma evansi* in Malaysia. *Malays. Applied Biology* 10: 1-8
- Jones, K. E., Patel, N. G. & Levy, M. A. (2008). Global trends in emerging infectious diseases. *Nature*. 451: 990-993
- Nagaraja H.S., Anupama B.K. & Jeganathan. P.S. (2006). Stress responses in albino rats. *Thai J Physiol Sci.* 2006;19(2):8–15

- Arsad, S.S., Esa, N.M. & Hamzah, H. 2014. Histopathologic changes in liver and kidney tissues from male sprague dawley rats treated with *Rhaphidophora decursiva* (Roxb.) schott extract. *J Cytol Histol.* 4(1):10–18
- Chen, H.C., Chang, M.D. & Chang, T.J. 1985. Antibacterial properties of some spice plants before and after heat treatment. *Journal of Pharmacology.* 18: 190-195.
- Fevre, E.M., Coleman, P.G., Welburn, S.C. & Maudlin, I. 2004. Reanalyzing the 1900-1920 sleeping sickness epidemic in Uganda. *Emerging infectious diseases.* 10 (4). p. 567-571.
- Mitsumari, K., Shibutani, S., & Sato, S. (1998). Relationship between the development of hepatorenal toxicity and cadmium accumulation in rats. *Arch Toxicol.* 72(9):545–552.
- Romão, P.R.T., Tovar, J. Fonseca, S.G. Moraes, R.H., Cruz, A.K., Hothersall, J.S., -Noronha-Dutra, A.A., Ferreira, S.H. & Cunha, F.Q. 2006. Glutathione and the redox control system trypanothione/trypanothione reductase are involved in the protection of *Leishmania* spp. against nitrosothiol-induced cytotoxicity. *Brazilian Journal of Medical and Biological Research* 39(3): 355-363.
- Talakal. T.S., Dwivedi, S.K. & Sharma, S R. 2000. *in vitro* and *in vivo* antitrypanosoma potential of nyctanthes arbor-tristis leaves. *Pharmaceutical Biology.* 38: 326-329
- Wolfe, N.D., Dunavan, C.P. & Diamond, J. 2007. Origins of major human infectious diseases. *Nature.* 447: 279-283
- Verma, B.B., Gautam, O.P. & Malik P.D. 1976. *Trypanosoma evansi*: therapeutic efficacy of diaminazine aceturate in crossbred calves, *Bos Taurus* and *B. indicus*. *Experimental Parasitology* 40: 406-410.
- Taylor, L.H., Latham, S.M. & Woolhouse, M.E. 2001. Risk Factors for Human Disease Emergence. *Philos Trans R Soc Lond B Biol Sci.* 356(1411): 983-989
- Anonymous. 2003. *Universiti Kebangsaan Malaysia Animal Ethics Committee Guidelines (UKMAEC)*. UKMAEC Secretariat, Kuala Lumpur, 1-40



الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونِيْٓبَرْسِيْتِيْ اِسْلَامِيْ اِنْتَارْ اِنْجِيْسِيَا مَلِيْسِيَا

Malaysian Society of
Applied Biology



UNIVERSITI
KEBANGSAAN
MALAYSIA
National University of Malaysia



ACKNOWLEDGEMENT



الجامعة الإسلامية العالمية ماليزيا
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA
يُونَيْتِيسِي إِسْلَامِي أَنْتَارَايَحْسِيَا مَلَيْسِيَا

Malaysian Society of
Applied Biology



THANK YOU

‘Variable Surface Glycoprotein’ (VSG)


- Survival factor of *Trypanosoma* spp. in the infected host
- High density layer on the parasite cell membrane
- Contained 1×10^9 similar & uniformed glycoprotein molecules expressed by VSG-Trypanosome gene
- Protect the parasite from being identified/action of the host immune system
- Similar & uniformed glycoprotein molecule → only end region of ‘N-terminal loops’ structure (300-500 amino acid structures) can be identified by the host immune systems → specific antibody-antigen mechanisms

‘Variable Surface Glikoprotein’ (VSG) – cont.

- When the end region of `N-terminal loops’ structure being identified by the host immune systems → VSG-‘stochastic genetic modification’ of the parasite plays the role.
- VSG stochastic genetic modification = periodic changes of antigenic variation → the structures & characteristics of parasite cell membrane was modified whenever confronted with the host’s specific immune system which may varies.
- Periodic changes of antigenic variation → changes in parasitemia waves → longer survival time of the parasite → chronic infection on host

Survival Pattern of the Trypanosomiasis Infected-Host Due to VSG-Stochastic Genetic Modification Phenomenon

Effectuation of the changes in host's specific immune system



Day of Infection

Mechanism of Trypanosome VSG-stochastic genetic modification